Mary Spellman

Mary Spellman

Company: Castle Creek BioSciences

Job title: Chief Medical Officer


Autologous Gene Therapy for the Treatment of Dystrophic Epidermolysis Bullosa 9:30 am

• Outlining the scientific basis and mechanism of action for localized gene therapy for epidermolysis bullosa • Describing meaningful clinical study endpoints and trial design to assess the safety and efficacy of the technology • Identifying opportunities to advance gene therapy for cutaneous diseasesRead more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.